Clinical Trial Update: Study of the Safety and Efficacy of the Subunit Recombinant Tuberculosis Vaccine GamTBvac [Phase 3]

View source ↗

Summary

Phase 3 trial update for the subunit recombinant Tuberculosis vaccine GamTBvac evaluating safety and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• GamTBvac (recombinant subunit tuberculosis vaccine)

Snippet

Sponsor: Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Conditions: Tuberculosis | Phase 3 | Status: UNKNOWN